ARAF — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL937568	0.81	2/20
SCHEMBL169157	0.65	2/20
SCHEMBL548256	0.65	2/20
SCHEMBL940018	0.65	2/20
SCHEMBL171199	0.65	2/20
SCHEMBL545646	0.54	2/20
SCHEMBL546771	0.54	2/20
SCHEMBL545174	0.54	2/20
Hydrochloric Acid (SCHEMBL545435)	0.54	2/20
SCHEMBL545989	0.53	2/20
SCHEMBL364772	0.53	2/20
SCHEMBL547348	0.51	2/20
SCHEMBL374367	0.50	2/20
SCHEMBL545010	0.49	2/20
SCHEMBL1026182	0.48	2/20
SCHEMBL374495	0.47	2/20
SCHEMBL274235	0.46	2/20
SCHEMBL1078263	0.37	2/20
Gw305074X (SCHEMBL149921)	1.00	1/20
Gw305074X (SCHEMBL149922)	1.00	1/20

Clinical trials — most relevant to ARAF by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer	PHASE2	COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)	PHASE2	NOT_YET_RECRUITING
A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma	PHASE2	UNKNOWN
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma	PHASE2	COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas	PHASE1/PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Ulixertinib in People With Histiocytic Neoplasms	PHASE2	RECRUITING
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment	PHASE2	COMPLETED
STA-9090(Ganetespib) in Metastatic Ocular Melanoma	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer	PHASE2	COMPLETED
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer	PHASE2	COMPLETED
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma	PHASE1/PHASE2	COMPLETED
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC	PHASE2	UNKNOWN
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults	PHASE1	NOT_YET_RECRUITING
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults	PHASE1	NOT_YET_RECRUITING
A Study of ASN007 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)	PHASE1	COMPLETED
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer	PHASE1	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation	nan	COMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ARAF binder may also engage these)

Protein	Name	Similarity
O19004	—	1.000	O19004 →
P14056	—	1.000	P14056 →
P04627	—	1.000	P04627 →
P28028	—	0.997	P28028 →
P34908	—	0.996	P34908 →
Q04982	—	0.994	Q04982 →
BRAF	Serine/threonine-protein kinase B-raf	0.990	landscape →
P11345	—	0.989	P11345 →
A7E3S4	—	0.989	A7E3S4 →
Q5R5M7	—	0.988	Q5R5M7 →
Q99N57	—	0.987	Q99N57 →
RAF1	RAF proto-oncogene serine/threonine-protein kinase	0.987	landscape →
O54785	—	0.986	O54785 →
P27966	—	0.985	P27966 →
P09560	—	0.984	P09560 →
P53669	—	0.983	P53669 →
Q8QFP8	—	0.982	Q8QFP8 →
P10533	—	0.981	P10533 →
P53668	—	0.981	P53668 →
P05625	—	0.981	P05625 →
LIMK2	LIM domain kinase 2	0.979	landscape →
LIMK1	LIM domain kinase 1	0.979	landscape →
Q32L23	—	0.977	Q32L23 →
Q8BPM2	—	0.977	Q8BPM2 →
Q9ESL4	—	0.977	Q9ESL4 →
P53666	—	0.976	P53666 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.976	landscape →
Q9Z138	—	0.976	Q9Z138 →
MAP4K3	Mitogen-activated protein kinase kinase kinase kinase 3	0.976	landscape →
Q01974	—	0.976	Q01974 →